Based on these observations we decided to express HER3 ECD subdomains as paired I+II and III+IV subdomains in a eukaryotic system and produce polyclonal antibodies trying to find out whether these antibodies can mimic the combination strategy and display differential inhibitory activity on HER3 expressing tumor cell lines. The gene discussed is ERBB3; the disease is neoplasm.